Compare Celsius Holdings, Inc. (CELH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs TG Therapeutics Inc — how do they compare? Celsius Holdings, Inc. trades at $27.65 (market cap $7.11B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Celsius Holdings, Inc. and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | TGTX | |
|---|---|---|
Market Cap | $7.11B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $59.06 |
52-Week Low | $23.77 | $26.94 |
Enterprise Value | $8.90B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.48, up 0.99% on the day, but remains under bearish technical pressure with key resistance at $29. The company reported Q2 2026 earnings that missed expectations, with revenue growth slowing to 11% year-over-year as core brand sales weakened, though Alani Nu and Rockstar acquisitions provided some offset. Net cash flow was negative $350.20 million in 2025 due to significant investing activities.
Outlook is mixed; strong analyst buy consensus (95.65%) and a $44.08 price target suggest long-term confidence in growth via PepsiCo partnership, but near-term risks include execution challenges, margin pressure, and ongoing investigations into management disclosures. The stock's high P/E of 122.13 reflects growth expectations that must materialize to justify valuation.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
